Alnylam Pharma (ALNY) Tops Q3 EPS by 5c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $286.41 --0%
Revenue Growth %: +70.6%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: +70.6%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.58), $0.05 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $11 million versus the consensus estimate of $8.93 million.
At September 30, 2014, Alnylam had cash, cash equivalents and total marketable securities of $915.2 million, as compared to $350.5 million at December 31, 2013.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- NVE Corporation names new CEO and expands board to seven members
- Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
